Work

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-157713

Authors: Paula Rodríguez Otero, Nisha S. Joseph, Shaji K Kumar, Hans C. Lee, Xavier Leleu, Salomon Manier, Meletios A. Dimopoulos, María Victoria Mateos, Albert Oriol, Naresh Bumma, Weiying Gong, Pourab Roy, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn M. Sarkaria

Institutions: Clinica Universidad de Navarra, Universidad de Navarra, Winship Cancer Institute, Mayo Clinic, The University of Texas MD Anderson Cancer Center, Centre Hospitalier Universitaire de Poitiers, Centre Hospitalier Universitaire de Lille, Complejo Hospitalario de Salamanca, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Regeneron (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310127686

FWCI: 1.09

Cites:

Cited by: 7

Related to: 10